Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap in platinum-resistant and topotecan/liposomal doxorubicin-resistant advanced ovarian cancer
2005-005024-14Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aflibercept in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sanofi. Primary endpoint: Confirmed objective response rate. Started Feb 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-005024-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005024-14.